Radiopharmaceuticals are becoming an essential tool in the fight against cancer, and the field has been diversified with the investigation of f-block elements over the past decade. Here we discuss the highlights in 2023 research leading the charge in utilizing f-block elements in innovative ways, changing how we treat these diseases.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Goldsmith, S. J. Targeted radionuclide therapy: A historical and personal review. Semin. Nucl. Med. 50, 87–97 (2020).
Amoroso, A. J., Fallis, I. A. & Pope, S. J. A. Chelating agents for radiolanthanides: Applications to imaging and therapy. Coord. Chem. Rev. 340, 198–219 (2017).
Meyer, C. et al. Tandem isotope therapy with 225Ac- and 177Lu-PSMA-617 in a murine model of prostate cancer. J. Nucl. Med. 64, 1772–1778 (2023).
Tschan, V. J. et al. Albumin-binding and conventional PSMA ligands in combination with 161Tb: Biodistribution, dosimetry, and preclinical therapy. J. Nucl. Med. 64, 1625–1631 (2023).
Müller, C. et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 46, 1919–1930 (2019).
Kurtz, K. et al. Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications. Theranostics 13, 5469–5482 (2023).
Gefen, T. et al. The effect of haptens on protein-carrier immunogenicity. Immunology 144, 116–126 (2015).
Acknowledgements
We would like to acknowledge the support of the Department of Energy, Office of Science, Office of Basic Energy Sciences, Chemical Sciences, Geosciences, and Biosciences Division, Heavy Element Chemistry Program at the Lawrence Berkeley National Laboratory (LBNL) under contract DE-AC02-05CH11231.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Rigby, A., Arino, T. Harnessing the power of f-block elements in radiopharmaceuticals. Nat Rev Chem 8, 302–303 (2024). https://doi.org/10.1038/s41570-024-00601-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41570-024-00601-6